Anti-NFkB p100 / p52 antibody (ab86090)

Overview

  • Product nameAnti-NFkB p100 / p52 antibody
    See all NFkB p100 / p52 primary antibodies
  • Description
    Rabbit polyclonal to NFkB p100 / p52
  • Tested applicationsSuitable for: IHC-P, WBmore details
  • Species reactivity
    Reacts with: Mouse, Human
  • Immunogen

    Synthetic peptide selected from the N-terminal region of Mouse NFkB p100/ p52 conjugated to KLH (NP_062281.1).

  • Positive control
    • A375 cell line lysates; Human hepatocarcinoma tissue.

Properties

Applications

Our Abpromise guarantee covers the use of ab86090 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-P 1/50 - 1/100.
WB 1/100 - 1/500. Predicted molecular weight: 97 kDa.

Target

  • FunctionNF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. In a non-canonical activation pathway, the MAP3K14-activated CHUK/IKKA homodimer phosphorylates NFKB2/p100 associated with RelB, inducing its proteolytic processing to NFKB2/p52 and the formation of NF-kappa-B RelB-p52 complexes. The NF-kappa-B heterodimeric RelB-p52 complex is a transcriptional activator. The NF-kappa-B p52-p52 homodimer is a transcriptional repressor. NFKB2 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p100 and generation of p52 by a cotranslational processing. The proteasome-mediated process ensures the production of both p52 and p100 and preserves their independent function. p52 binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3', located in the enhancer region of genes involved in immune response and acute phase reactions. p52 and p100 are respectively the minor and major form; the processing of p100 being relatively poor. Isoform p49 is a subunit of the NF-kappa-B protein complex, which stimulates the HIV enhancer in synergy with p65.
  • Involvement in diseaseNote=A chromosomal aberration involving NFKB2 is found in a case of B-cell non Hodgkin lymphoma (B-NHL). Translocation t(10;14)(q24;q32) with IGHA1. The resulting oncogene is also called Lyt-10C alpha variant.
    Note=A chromosomal aberration involving NFKB2 is found in a cutaneous T-cell leukemia (C-TCL) cell line. This rearrangement produces the p80HT gene which encodes for a truncated 80 kDa protein (p80HT).
    Note=In B-cell leukemia (B-CLL) cell line, LB40 and EB308, can be found after heterogeneous chromosomal aberrations, such as internal deletions.
  • Sequence similaritiesContains 7 ANK repeats.
    Contains 1 death domain.
    Contains 1 RHD (Rel-like) domain.
  • DomainThe C-terminus of p100 might be involved in cytoplasmic retention, inhibition of DNA-binding by p52 homodimers, and/or transcription activation.
    The glycine-rich region (GRR) appears to be a critical element in the generation of p52.
  • Post-translational
    modifications
    While translation occurs, the particular unfolded structure after the GRR repeat promotes the generation of p52 making it an acceptable substrate for the proteasome. This process is known as cotranslational processing. The processed form is active and the unprocessed form acts as an inhibitor (I kappa B-like), being able to form cytosolic complexes with NF-kappa B, trapping it in the cytoplasm. Complete folding of the region downstream of the GRR repeat precludes processing.
    Subsequent to MAP3K14-dependent serine phosphorylation, p100 polyubiquitination occurs then triggering its proteasome-dependent processing.
    Constitutive processing is tightly suppressed by its C-terminal processing inhibitory domain, named PID, which contains the death domain.
  • Cellular localizationNucleus. Cytoplasm. Nuclear, but also found in the cytoplasm in an inactive form complexed to an inhibitor.
  • Information by UniProt
  • Database links
  • Alternative names
    • CVID10 antibody
    • DNA binding factor KBF2 antibody
    • DNA-binding factor KBF2 antibody
    • H2TF1 antibody
    • Lymphocyte translocation chromosome 10 antibody
    • Lymphocyte translocation chromosome 10 protein antibody
    • Lyt 10 antibody
    • Lyt10 antibody
    • NF kB2 antibody
    • NFKB2 antibody
    • NFKB2_HUMAN antibody
    • Nuclear factor NF kappa B p100 subunit antibody
    • Nuclear factor NF kappa B p52 subunit antibody
    • Nuclear factor NF-kappa-B p52 subunit antibody
    • Nuclear factor of kappa light chain gene enhancer in B cells 2 antibody
    • Nuclear factor of kappa light polypeptide gene enhancer in B cells 2 antibody
    • Nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 antibody
    • Oncogene Lyt 10 antibody
    • Oncogene Lyt-10 antibody
    • p105 antibody
    • p49/p100 antibody
    see all

Anti-NFkB p100 / p52 antibody images

  • Anti-NFkB p100 / p52 antibody (ab86090) at 1/100 dilution + A375 cell line lysates at 35 µg

    Predicted band size : 97 kDa
  • ab86090 at 1/50 dilution, staining NFkB p100 / p52 in Human hepatocarcinoma by Immunohistochemistry, Formalin-fixed, Paraffin-embedded tissue, followed by peroxidase-conjugated secondary antibody and DAB staining.

References for Anti-NFkB p100 / p52 antibody (ab86090)

ab86090 has not yet been referenced specifically in any publications.

Product Wall

Application Immunocytochemistry/ Immunofluorescence
Sample Human Cell (MIO-M1 Mueller cells)
Permeabilization Yes - 0.1% Tx-100
Specification MIO-M1 Mueller cells
Blocking step Serum as blocking agent for 30 minute(s) · Concentration: 5%
Fixative Paraformaldehyde
Username

Abcam user community

Verified customer

Submitted Dec 30 2015

Application Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)
Blocking step Serum as blocking agent for 30 minute(s) · Concentration: 5% · Temperature: RT°C
Antigen retrieval step Heat mediated - Buffer/Enzyme Used: 10mM Tris, 1mM EDTA pH 9
Sample Monkey Tissue sections (retina)
Specification retina
Permeabilization No
Fixative Paraformaldehyde
Username

Abcam user community

Verified customer

Submitted Feb 06 2015

Application Western blot
Loading amount 200 µg
Gel Running Conditions Reduced Denaturing (4-15% SDS-PAGE)
Sample Monkey Tissue lysate - whole (retina)
Specification retina
Blocking step Milk as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: RT°C
Username

Abcam user community

Verified customer

Submitted Feb 06 2015

Application Western blot
Loading amount 30 µg
Gel Running Conditions Reduced Denaturing (8% Gel)
Sample Mouse Cell lysate - whole cell (WT & TRAF2 KO embryonic fibroblasts and macrophage)
Specification WT & TRAF2 KO embryonic fibroblasts and macrophage
Treatment TNFα, BV6, LPS and PAM-CSK4 for 24hrs
Blocking step Milk as blocking agent for 15 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 4°C
Username

Ms. Anna McCormick

Verified customer

Submitted Oct 10 2013

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"